Literature DB >> 17010972

Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease.

Chang-Lin Liang1, Tom T Wang, Kate Luby-Phelps, Dwight C German.   

Abstract

In Parkinson's disease (PD) there is a selective loss of certain midbrain dopaminergic (DA) neurons. The most vulnerable neurons reside in the substantia nigra zona compacta (SNC), whereas the DA neurons in the ventral tegmental area (VTA) and interfascicular (IF) nucleus are less vulnerable to degeneration. Many sporadic PD patients have a defect in mitochondria respiration, and some of the genes that cause PD are mitochondrial-related (e.g., PINK1, Parkin, DJ1). The present study sought to determine whether mitochondria mass is different in SNC neurons compared to other midbrain DA neurons and to non-DA neurons in the mouse. At the electron microscopic level, mitochondria in the SN DA neurons occupy 40% less of the soma and dendritic area than in the SN non-DA neurons. The area occupied by mitochondria in the SN DA neurons is also lower than in the VTA neurons, although not different from the IF neurons. The red nucleus somata have the largest percentage of the somata occupied by mitochondria (12%). Mitochondria size is related to somata size; the largest mitochondria are found in the red nucleus neurons and the smallest mitochondria are found in the IF neurons. At the light microscopic level, SNC, VTA and IF DA neurons have <50% of the cytoplasm immunostained with the mitochondrial antibody 1D6, whereas non-DA neurons in the same midbrain regions contain mitochondria areas up to >65% of the cytoplasm area. These data indicate that mitochondria size and mass are not the same for all neurons, and the SNC DA neurons have relatively low mitochondria mass. The low mitochondria mass in SNC DA neurons may contribute to the selective vulnerability of these neurons in certain rodent models of PD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010972     DOI: 10.1016/j.expneurol.2006.08.015

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  71 in total

1.  Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson's disease.

Authors:  Annadurai Anandhan; Musthafa Mohamed Essa; Thamilarasan Manivasagam
Journal:  Neurotox Res       Date:  2012-06-06       Impact factor: 3.911

Review 2.  Axon degeneration in Parkinson's disease.

Authors:  Robert E Burke; Karen O'Malley
Journal:  Exp Neurol       Date:  2012-01-18       Impact factor: 5.330

3.  Quantification of mitochondrial morphology in neurites of dopaminergic neurons using multiple parameters.

Authors:  Lyle Wiemerslage; Daewoo Lee
Journal:  J Neurosci Methods       Date:  2016-01-14       Impact factor: 2.390

4.  Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress.

Authors:  Jaime N Guzman; Ema Ilijic; Ben Yang; Javier Sanchez-Padilla; David Wokosin; Dan Galtieri; Jyothisri Kondapalli; Paul T Schumacker; D James Surmeier
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

Review 5.  Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models.

Authors:  Ruben K Dagda; Jianhui Zhu; Charleen T Chu
Journal:  Mitochondrion       Date:  2009-06-27       Impact factor: 4.160

Review 6.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 7.  The pathology roadmap in Parkinson disease.

Authors:  D James Surmeier; David Sulzer
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

Review 8.  Dysfunction of the neurovascular unit in ischemic stroke and neurodegenerative diseases: An aging effect.

Authors:  Wei Cai; Kai Zhang; Peiying Li; Ling Zhu; Jing Xu; Boyu Yang; Xiaoming Hu; Zhengqi Lu; Jun Chen
Journal:  Ageing Res Rev       Date:  2016-09-30       Impact factor: 10.895

Review 9.  Mitochondrial quality control: insights on how Parkinson's disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis.

Authors:  Ruben K Dagda; Charleen T Chu
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

Review 10.  Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.

Authors:  D James Surmeier; Jaime N Guzman; Javier Sanchez-Padilla
Journal:  Cell Calcium       Date:  2010-01-06       Impact factor: 6.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.